Technical Analysis for GRFS - Grifols, S.A.

Grade Last Price % Change Price Change
grade C 20.68 1.42% 0.29
GRFS closed up 1.42 percent on Thursday, October 17, 2019, on 54 percent of normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Down Up
See historical GRFS trend table...

Date Alert Name Type % Chg
Overbought Stochastic Strength 0.00%
Overbought Stochastic Strength 1.42%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.44%
Pocket Pivot Bullish Swing Setup 0.44%
Stochastic Reached Overbought Strength 0.44%
Overbought Stochastic Strength 0.44%
Up 3 Days in a Row Strength 0.44%
Pocket Pivot Bullish Swing Setup 1.22%
Crossed Above 20 DMA Bullish 1.62%
Gapped Up Strength 1.62%

Older signals for GRFS ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Grifols, S.A., a specialty biopharmaceutical company, develops, manufactures, and distributes a range of plasma derivative products primarily in the European Union, Spain, the United States, and Canada. It specializes in providing infusion solutions, nutrition products, medical devices, and diagnostic instrumentation and reagents for use in hospitals and clinics. The company operates in four divisions: Bioscience, Diagnostic, Hospital, and Raw Materials and Others. The Bioscience division manufactures and sells plasma derivatives for therapeutic use, including the reception, analysis, quarantine, classification, fractionation, and purification of plasma; and sells and distributes end products. This division offers plasma products, such as IVIG, Factor VIII, A1PI, and albumin; and intramuscular immunoglobulins, ATIII, Factor IX, and plasma thromboplastin components. The Diagnostic division focuses on researching, developing, manufacturing, and marketing in vitro diagnostics products, such as analytical instruments and reagents for diagnostics, as well as blood bank products. This division serves blood donation centers, clinical analysis laboratories, and hospital immunohematology services. The Hospital division manufactures and installs products used by and in hospitals comprising parenteral solutions, and enteral and parenteral nutritional fluids. The Raw Materials and Others division engages in the sale of intermediate pastes and plasma to third parties. The company's products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and a range of other medical conditions. The company was formerly known as Probitas Pharma, S.A. and changed its name to Grifols, S.A. in 2005. Grifols, S.A. was founded in 1940 and is headquartered in Barcelona, Spain.
Medicine Biopharmaceutical Medical Specialties Infectious Diseases Healthcare Providers Antibody Nutrition Products End Products European Union Hemophilia Transfusion Medicine Ibex 35 In Vitro Diagnostics Plasma Products
Is GRFS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 23.03
52 Week Low 17.42
Average Volume 1,291,946
200-Day Moving Average 19.9176
50-Day Moving Average 20.8234
20-Day Moving Average 20.177
10-Day Moving Average 20.2
Average True Range 0.3434
ADX 19.53
+DI 26.296
-DI 19.7126
Chandelier Exit (Long, 3 ATRs ) 19.9298
Chandelier Exit (Short, 3 ATRs ) 20.4752
Upper Bollinger Band 20.8379
Lower Bollinger Band 19.5161
Percent B (%b) 0.88
BandWidth 6.551023
MACD Line -0.0777
MACD Signal Line -0.2053
MACD Histogram 0.1276
Fundamentals Value
Market Cap 28.25 Billion
Num Shares 1.37 Billion
EPS 0.49
Price-to-Earnings (P/E) Ratio 42.20
Price-to-Sales 5.73
Price-to-Book 6.87
PEG Ratio 1.34
Dividend 0.33
Dividend Yield 1.60%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 21.04
Resistance 3 (R3) 21.01 20.85 20.98
Resistance 2 (R2) 20.85 20.76 20.87 20.96
Resistance 1 (R1) 20.77 20.70 20.81 20.80 20.94
Pivot Point 20.61 20.61 20.63 20.63 20.61
Support 1 (S1) 20.53 20.52 20.57 20.56 20.42
Support 2 (S2) 20.37 20.46 20.39 20.40
Support 3 (S3) 20.29 20.37 20.38
Support 4 (S4) 20.32